Literature DB >> 2943309

Effects of paroxetine on human sleep.

I Oswald, K Adam.   

Abstract

In a first double-blind, balanced order study, 12 subjects, mean age 57 years, took placebos at bedtime on 2 nights, paroxetine 15 mg on 2 nights and paroxetine 30 mg on 2 nights. In a second study, 12 subjects, mean age 56 years, took placebos on 2 mornings and paroxetine 30 mg on 2 mornings. Electrophysiological measures of all-night sleep were made on each night subsequent to medication. Paroxetine caused more frequent awakenings, reduced total sleep and strongly suppressed REM sleep, especially the 30 mg dosage. When it had been taken in the morning, paroxetine additionally delayed sleep onset and increased slow-wave sleep.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943309      PMCID: PMC1401077     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Viloxazine, sleep, and subjective feelings.

Authors:  V Brezinová; K Adam; K Chapman; I Oswald; J Thomson
Journal:  Psychopharmacology (Berl)       Date:  1977-12-19       Impact factor: 4.530

2.  Changes during weeks in effects of tricyclic drugs on the human sleeping brain.

Authors:  D L Dunleavy; V Brezinova; I Oswald; A W Maclean; M Tinker
Journal:  Br J Psychiatry       Date:  1972-06       Impact factor: 9.319

3.  Chronic fenfluramine administration: some cerebral effects.

Authors:  S A Lewis; I Oswald; D L Dunleavy
Journal:  Br Med J       Date:  1971-07-10

4.  Trazodone enhances sleep in subjective quality but not in objective duration.

Authors:  I Montgomery; I Oswald; K Morgan; K Adam
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

5.  Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.

Authors:  A L Laursen; P L Mikkelsen; S Rasmussen; P le Fèvre Honoré
Journal:  Acta Psychiatr Scand       Date:  1985-03       Impact factor: 6.392

6.  An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.

Authors:  C Børup; B Meidahl; I M Petersen; A Vangtorp; P le Fèvre Honoré
Journal:  Pharmacopsychiatria       Date:  1982-11
  6 in total
  8 in total

1.  Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Authors:  Szilvia Vas; Zita Kátai; Diána Kostyalik; Dorottya Pap; Eszter Molnár; Péter Petschner; Lajos Kalmár; György Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

2.  The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.

Authors:  A L Sharpley; D J Williamson; M E Attenburrow; G Pearson; P Sargent; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

3.  Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial.

Authors:  William V McCall; Ruth M Benca; Peter B Rosenquist; Nagy A Youssef; Laryssa McCloud; Jill C Newman; Doug Case; Meredith E Rumble; Steven T Szabo; Marjorie Phillips; Andrew D Krystal
Journal:  Am J Psychiatry       Date:  2019-09-20       Impact factor: 18.112

Review 4.  Antidepressants and sleep: a qualitative review of the literature.

Authors:  Sue Wilson; Spilios Argyropoulos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

7.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 8.  Major depressive disorder: mechanism-based prescribing for personalized medicine.

Authors:  Philip F Saltiel; Daniel I Silvershein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-31       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.